Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Lung Neoplasms 13Colorectal Neoplasms 11Neoplasms 8Mesothelioma, Malignant 7Mesothelioma 7Meningeal Carcinomatosis 7Neoplasm Metastasis 6Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Stomach Neoplasms 3Pancreatic Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2NSCLC 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Solid Tumor 2Urologic Neoplasms 1Solitary Fibrous Tumor, Pleural 1Rectal Neoplasms 1

Interventions

selpercatinib 2pembrolizumab 2abemaciclib 2Pemetrexed 2Nivolumab 2Irinotecan 2Fulvestrant 2Abiraterone Acetate 2ribociclib 1repotrectinib 1relatlimab 1pralsetinib 1pamiparib 1palbociclib 1osimertinib 1onapristone 1olaparib 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1exemestane 1enzalutamide 1elacestrant 1cobimetinib 1abiraterone 1Trastuzumab 1Taxes 1Tamoxifen 1STX-478 1Radiation 1RAD1901 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Site × Pemetrexed × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡